Gene-edited immune cells could help wipe out deadly tumors

  • Thread starter Thread starter Greg Bernhardt
  • Start date Start date
  • Tags Tags
    Cells Crispr
Click For Summary
SUMMARY

The University of Pennsylvania is set to initiate the first human trial in the U.S. using CRISPR gene-editing technology to enhance immune cells for cancer treatment. This groundbreaking study will involve up to 18 patients with multiple myeloma, sarcoma, and melanoma. The approach builds on CAR-T immunotherapy, which has recently seen FDA approvals for blood cancer treatments. Unlike traditional CAR-T methods that randomly insert genes, CRISPR allows for precise gene insertion, minimizing unintended side effects and potentially increasing the efficacy of T-cells against tumors.

PREREQUISITES
  • Understanding of CRISPR gene-editing technology
  • Familiarity with CAR-T immunotherapy
  • Knowledge of cancer types: multiple myeloma, sarcoma, and melanoma
  • Awareness of FDA approval processes for medical treatments
NEXT STEPS
  • Research the latest advancements in CRISPR technology and its applications in oncology
  • Explore the mechanisms and outcomes of CAR-T therapies approved by the FDA
  • Investigate the ethical considerations surrounding gene editing in humans
  • Study the clinical trial process and patient enrollment criteria for cancer therapies
USEFUL FOR

Oncologists, researchers in gene therapy, medical professionals involved in clinical trials, and anyone interested in the future of cancer treatment through innovative technologies.

Messages
19,910
Reaction score
10,919
U.S. Doctors Plan to Treat Cancer Patients Using CRISPR
https://www.technologyreview.com/s/...chnologies-wont-lead-designer-babies/']crispr/[/URL]

The first human test in the U.S. involving the gene-editing tool CRISPR could begin at any time and will employ the DNA cutting technique in a bid to battle deadly cancers.

Doctors at the University of Pennsylvania say they will use CRISPR to modify human immune cells so that they become expert cancer killers, according to plans posted this week to a directory of ongoing clinical trials.

The study will enroll up to 18 patients fighting three different types of cancer—multiple myeloma, sarcoma, and melanoma—in what could become the first medical use of CRISPR outside China, where similar studies have been under way.
 
  • Like
Likes   Reactions: Choppy, Drakkith, jerromyjon and 3 others
Biology news on Phys.org
This research builds upon earlier work on CAR-T cancer immunotherapy, in which doctors genetically engineer a patient's own immune cells to better fight cancer. Earlier this year, two CAR-T therapies were approved by the FDA to treat two types of blood cancer, and many more therapies are in the pipeline for clinical testing. Current CAR-T therapies use relatively imprecise genetic engineering methods to randomly insert the new genes into the DNA of T-cells. While effective, the random insertion of the gene can cause potentially disrupt important genes in the T-cells and cause unintended side effects. Using https://www.cancer.gov/news-events/cancer-currents-blog/2017/https://www.physicsforums.com/insights/dont-fear-crispr-new-gene-editing-technologies-wont-lead-designer-babies/-immunotherapy to precisely insert the new gene into a specific location in the DNA of the T-cells can avoid these unintended effects and has been shown to create T-cells that are more potent at fighting tumors.
 
  • Like
Likes   Reactions: Buzz Bloom and Greg Bernhardt

Similar threads

  • · Replies 13 ·
Replies
13
Views
4K
  • · Replies 11 ·
Replies
11
Views
6K
  • · Replies 2 ·
Replies
2
Views
5K
  • · Replies 2 ·
Replies
2
Views
5K
  • · Replies 1 ·
Replies
1
Views
3K
  • · Replies 1 ·
Replies
1
Views
2K
  • · Replies 19 ·
Replies
19
Views
9K
  • · Replies 1 ·
Replies
1
Views
3K
  • · Replies 2 ·
Replies
2
Views
2K